

Attorney Docket No.: 6555.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Markussen et al.

Serial No.: 10/719,601

Group Art Unit: 1653

Filed: November 21, 2003

Examiner: To be assigned

For: Method for Purifying a Fermentation-Derived Product

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **May 6, 2004**

Gwendolyn Wardell-O'Neal
(name of person mailing paper)

(signature of person mailing paper)



Attorney Docket No.: 6555.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Markussen et al.

Application No.: 10/719,601

Group Art Unit: 1653

Filed: November 21, 2003

Examiner: To be assigned

For: Method for Purifying a Fermentation-Derived Product

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US Patent No. 5,455,331
2. EP 0431679 A1
3. EP 0438767 A2
4. EP 0438767 A3
5. EP 0438767 B1
6. EP 0699687 A2


7. EP 0699687 A3
8. EP 1329462 A1
9. WO 90/00200
10. JP 10101696 A (Shinotesuto:KK; Japan Found Cancer Res), April 21,1998 abstract

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: May 6, 2004

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Serial No.

(Use several sheets if necessary)

Filing Date

Group

EXISTENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,455,331	10-03-95	Pearce	530	366	

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		EP 0 431 679 A1	11-28-90	EP				
		EP 0 438 767 A2	12-22-90	EP				
		EP 0 438 767 A3	12-22-90	EP				
		EP 0 438 767 B1	12-22-90	EP				
		EP 0 699 687 A2	08-30-95	EP				
		EP 0 699 687 A3	08-30-95	EP				
		EP 1 329 462 A1	10-24-01	EP				
		WO 90/00200 A1	01-11-90	PCT				
		JP 10101696 A	04-21-98	JP			Ab- stract	

[illegible]

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.